Massive Bio
Uses AI to match cancer patients with clinical trials globally, expanding access.
What they do
Massive Bio provides an artificial intelligence-driven platform that matches cancer patients to clinical trials. Pharmaceutical companies, contract research organizations, and oncology practices use this service to accelerate patient recruitment and connect individuals to novel, targeted cancer therapies regardless of geographic location.
The record
- Vertical
- Oncology
- Sub-segment
- Clinical trial matching
- Product type
- Service
- Stage
- Series B
- Headquarters
- New York, United States
- Region
- North America
- Founded
- 2014
- Total funding
- $23M raised
Notable investors: Revo Capital, SBA Group, Kiraco, DEG.